Last reviewed · How we verify
NCT03466775
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
trial testing Anti-angiotensin II type 1 receptor antibody measurement in Kidney Transplant Failure and Rejection in 1,845 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Paris Translational Research Center for Organ Transplantation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,845 |
| Start date | 1 January 2008 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Anti-angiotensin II type 1 receptor antibody measurement
- Measurement of ENDAT expression level allograft
- Allograft survival
- Allograft rejection appearance
Conditions studied
- Kidney Transplant Failure and Rejection — all drugs for Kidney Transplant Failure and Rejection →
Sponsor
Paris Translational Research Center for Organ Transplantation — full company profile →
Who can join
18 and older, any sex, with Kidney Transplant Failure and Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Incompatibility between non-genetically identical donors and recipients has been increasingly recognized as the main contributing factor to solid allograft rejection and failure, through the triggering of donor-specific responses mediated by T- and B-lymphocytes. The Human Leucocyte Antigen (HLA) system has been identified as the main target of donor-specific responses, especially through the production by the recipient of antibodies directed toward non-self donor HLA molecules expressed on the allograft endothelium. As a consequence, in organ transplantation, the current approach to immunological risk stratification, patient monitoring and rejection diagnosis is based on biomarkers derived from the HLA system. However, this approach does not provide a sufficient accuracy for the risk stratification and the diagnosis of immunological complications in solid organ transplantation, which still remain the dominant cause of allograft failure. A recent body of evidence supports that specific non-HLA antigens expressed on the allograft endothelium may be relevant to allograft rejection, suggesting that a new strategy to transplant diagnostic testing at a non-HLA level would help to overcome the limitations of the current HLA-based approach to immunological assessment of transplant recipients. Among antibodies to non-HLA endothelial antigens, angiotensin II type 1 receptor activating antibodies have been the most widely reported antibodies to associate with the occurrence of allograft rejection, dysfunction and loss, even if their independent role, with respect to the presence of concomitant anti-HLA antibodies, has not been demonstrated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03466775
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Failure and Rejection
Currently open trials in the same condition.
- NCT05325008 — A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients · Phase 3 · recruiting
- NCT03955172 — Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated · NA · recruiting
- NCT04526431 — Tacrolimus Pharmacokinetic Subpopulations · recruiting
- NCT04369612 — Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples · NA · recruiting
- NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting
Other Paris Translational Research Center for Organ Transplantation trials
Trials by the same sponsor.
- NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
- NCT07091214 — Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study · not yet recruiting
- NCT07269275 — HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes · completed
- NCT06496269 — Impact of Microvascular Inflammation on Kidney Allograft Outcome · completed
- NCT06436586 — Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03466775 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Paris Translational Research Center for Organ Transplantation
- Last refreshed: 15 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466775.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing